Cancer is a leading cause of death worldwide, resulting in∼ 10 million deaths in 2020.
Major oncogenic effectors are the Myc proto-oncogene family, which consists of three …

Polycomb repressive complex 2 (PRC2) is a multisubunit histone-modifying enzyme
complex that mediates methylation of histone H3 lysine 27 (H3K27). Trimethylated H3K27 …

The enhancer of zeste homolog 2 (EZH2) and its highly related homolog EZH1 are
considered to be epigenetic silencing factors, and they play key roles in the growth and …

The importance of EZH2 as a key methyltransferase has been well documented
theoretically. Practically, the first EZH2 inhibitor Tazemetostat (EPZ6438), was approved by …

NUT carcinoma is an aggressive carcinoma driven by the BRD4-NUT fusion oncoprotein,
which activates chromatin to promote expression of progrowth genes. BET bromodomain …

Multiple myeloma (MM) is the second most common hematological malignancy with poor
prognosis. Enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of polycomb …

Neuroblastoma is one of the commonest extra-cranial pediatric tumors, and accounts for
over 15% of all childhood cancer mortality. Risk stratification for children with neuroblastoma …

Simple Summary Cisplatin is a chemotherapy drug widely used in the treatment of different
cancer types. However, cisplatin displays a high range of toxicity and its use usually leads to …

MYCN amplification in neuroblastoma leads to aberrant expression of MYCN oncoprotein,
which binds active genes promoting transcriptional amplification. Yet, how MYCN …

Cancer cell heterogeneity is a major driver of therapy resistance. To characterize resistant
cells and their vulnerabilities, we studied the PLZF-RARA variant of acute promyelocytic …